Baxter Archives - Page 9 of 11 - Medical Design Sourcing

DTW Podcast: CEO Petrovic explains how Insulet is switching people to `Pods

Insulet CEO Shacey Petrovic says she didn’t jump immediately at the chance to join the company.

In an interview with the DeviceTalks Weekly Podcast, Petrovic, who was serving as CEO of a women’s health company when CEO-Patrick Sullivan, her former boss at Cytyc, called her with an offer to serve as Insulet’s chief commercial officer

“I said, `Well, Pat, I’m a CEO now, you know, didn’t you hear?,” she joked.

A chief commercial officer role might be seen as a backward step from CEO, but Sullivan framed the question differently. He told Petrovic that he came out of retirement to take the CEO role and didn’t want to a long stint as CEO. “He said, `This could be your opportunity to eventually run a public company. If it goes well, I need a successor, the technology is remarkable, and together we can fix this problem.’”

A path the CEO role at a publicly traded company was certainly appealing. But Petrovic had more personal reason for the jo…

Baxter wins FDA clearance for AK 98 hemodialysis machine

Baxter (NYSE:BAX) announced today that it recieved FDA clearance for its next-generation artificial kidney 98 (AK 98) dialysis machine.

Deerfield, Ill.-based Baxter’s AK 98 machine is designed as a portable and easy-to-use system to administer hemodialysis (HD) treatments.

It offers encrypted, two-way connectivity to enable the system to pull prescriptions directly from the electronic medical record for simplified workflow and data handling, according to a news release.

AK 98 includes features such as automatic alert resolution, which enables the machine to self-clear already corrected pressure alarms and avoid the unnecessary stoppage of treatment. Additionally, an intuitive customizable interface, a simple set-up process and a stable base design comprise the machine.

“We designed this latest version of our AK 98 system to help dialysis providers minimize the operational challenges that can come with administering multiple hemodialysis sess…

Baxter to make Moderna COVID-19 vaccine in US

Baxter announced that its Baxter BioPharma Solutions business will make Moderna‘s COVID-19 vaccine at its fill/finish sterile manufacturing facilities in Bloomington, Ind.

The plan — announced yesterday — is for Baxter to make 60–90 million doses of the Moderna vaccine in 2021.

“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for COVID-19,” said Marie Keeley, VP of Baxter BioPharma Solutions.

Get the full story on our sister site Pharmaceutical Processing World.

Baxter to make Moderna COVID-19 vaccine in US

Baxter announced that its Baxter BioPharma Solutions business will make Moderna‘s COVID-19 vaccine at its fill/finish sterile manufacturing facilities in Bloomington, Ind.

The plan — announced yesterday — is for Baxter to make 60–90 million doses of the Moderna vaccine in 2021.

“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for COVID-19,” said Marie Keeley, VP of Baxter BioPharma Solutions.

“Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine,” Keeley said in a news release.

Baxter’s 600,000 ft2, 700-employee campus in Bloomington has capabilities and expertise in parenteral delivery systems and clinical and commercial vaccine manufacturing — including preventive and seasonal vaccines for global markets.

The major COVID-19 vaccine makers have been making a host of manufa…

The top 7 medtech CEO quotes on COVID-19, one year later

The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out.

Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world in infections, accounting for 28.4 million cases. More than 2.5 million people have died from the virus globally. Medtech has been on the frontlines throughout the pandemic, whether it was shifting production to make ventilators or PPE or developing COVID-19 tests and vaccines.

More than a year since the virus’ appearance in the U.S., some medtech CEOs are gaining a better understanding of how the industry may look moving forward. From stockpiling to new COVID-19 variants posing risks, here are the insights from seven CEOs.

Next >>

The top 7 medtech CEO quotes on COVID-19, one year later

[Photo by Fusion Medical Animation on Unsplash]

The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out.

Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world in infections, accounting for 28.4 million cases. More than 2.5 million people have died from the virus globally. Medtech has been on the frontlines throughout the pandemic, whether it was shifting production to make ventilators or PPE or developing COVID-19 tests and vaccines.

More than a year since the virus’ appearance in the U.S., some medtech CEOs are gaining a better understanding of how the industry may look moving forward. From stockpiling to new COVID-19 variants posing risks, here are the insights from s…

MedTech 100 roundup: Index rebounds from dip with another all-time high

The end of January saw the first major dip for the medtech industry but the beginning of February brought yet another peak.

MassDevice‘s MedTech 100 index ended the week (Feb. 5) at 108.23 points, marking a 4% rise from the 104.05-point mark set at the end of the previous week (Jan. 29).

The final mark for the week sets an all-time best for the index, which had previously reached 106.81 points on Jan. 8, then 107.4 points on Jan. 20. The rise has been remarkable, considering the index had never reached even the 100-point mark before November 2020.

Medtech’s latest rise means the index has risen 17.2% from the pre-COVID-19 pandemic high of 92.32, set on Feb. 19, 2020. Additionally, the industry has very much rebounded from its lowest place, a 62.13-point mark at the start of the pandemic on March 23, 2020. Since that point, the industry has jumped 74.2%.

Here are some of the best-performing medtech stocks from 2020.

Medtech’s performanc…

Baxter ticks up on Street-beating Q4 results

Baxter (NYSE:BAX) posted fourth-quarter results today that beat the consensus forecast on Wall Street.

The Deerfield, Ill.-based company reported profits of $171 million, or 33¢ per share, on sales of $3.2 billion for the three months ended Dec. 31, 2020, for a sales growth of 4.7% compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were 80¢ ahead of The Street, where analysts were looking for sales of $3 billion.

“Amid an unprecedented global public health crisis, Baxter remains focused on advancing our mission for patients and driving value for all stakeholders,” president and CEO Joe Almeida said in a news release. “Our 2020 performance demonstrates the underlying strength of our portfolio, as well as our heightened agility and resilience fueled by our ongoing transformation. As we enter 2021, we remain focused on our strategy to accelerate sales through enhanced commercial execution and innovation as well as driving margin e…

BofA bullish on medtech as surgeries increase

Bank of America analysts say that they are bullish over the medtech industry as surgical procedure recoveries in recent months bode well for the field.

In an analysis published yesterday, BofA said medtech management teams are likely remaining cautiously optimistic amid recovery efforts brough on by the impact of COVID-19, but they are growing in confidence with regard to the quality and durability of demand for their products, with Medtronic’s (NYSE:MDT) recent earnings call and talks with Stryker (NYSE:SYK) suggesting the air of confidence.

Additionally, BofA analysts say that, as innovation pipelines are full, valuations in the industry remain reasonable, there is no drug pricing risk and medtech has outperformed the last three recessions.

Medtronic, Stryker and Baxter (NYSE:BAX) are three companies driving the narrative behind the BofA analysts’ confidence, but they did downgrade Intuitive Surgical (NSDQ:ISRG) from “Buy” to &#…

Baxter’s dialysis filter wins De Novo nod

Baxter (NYSE:BAX) announced today that it received FDA De Novo classification for its Theranova novel dialysis membrane.

Theranova is designed to deliver expanded hemodialysis (HDx) therapy, filtering a wider range of molecules from the blood than traditional hemodialysis (HD) filters, targeting certain molecules associated with inflammation and cardiovascular disease in patients with kidney failure, according to a news release.

HDx is similar to conventional HD, but has a change of the dialyzer membrane, allowing the Theranova’s “medium cut-off” membrane to combine high permeability and selectivity for uremic toxins while retaining essential proteins and maintaining albumin levels during treatment.

Deerfield, Ill.-based Baxter conducted a randomized, controlled study of Theranova in the U.S., evaluating safety and efficacy. After observing 172 hemodialysis patients who received therapy through either a medium cut-off dialyzer (Theranov…

The top 5 medtech CEO quotes about COVID-19

The latest earnings season not only provided insights from top medtech CEOs about how the COVID-19 pandemic is changing the industry, but also lessons learned going forward.

Here are five top quotes about lessons learned.

Next>>

DeviceTalks editorial director Tom Salemi contributed to this report.

The top 5 medtech CEO quotes about COVID-19

The latest earnings season not only provided insights from top medtech CEOs about how the COVID-19 pandemic is changing the industry, but also lessons learned going forward.

Here are five top quotes about lessons learned.

Next>>

DeviceTalks editorial director Tom Salemi contributed to this report.